Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Ms. Mirit Horenshtein Hadar | EVP of Finance Affairs, CFO & Secretary | 69.98k | -- | 1984 |
Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific & Development Officer | 206.8k | -- | 1954 |
Silexion Therapeutics Corp
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available